ファウチせんせから勇者の皆様にこっそり非常に残念なお知らせ

 Perspective| Volume 31, ISSUE 1, P146-157, January 11, 2023

Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses

• David M. Morens
• Jeffery K. Taubenberger
• Anthony S. Fauci

DOI:https://doi.org/10.1016/j.chom.2022.11.016

Summary

Viruses that replicate in the human respiratory mucosa without infecting systemically, including influenza A, SARS-CoV-2, endemic coronaviruses, RSV, and many other “common cold” viruses, cause significant mortality and morbidity and are important public health concerns. Because these viruses generally do not elicit complete and durable protective immunity by themselves, they have not to date been effectively controlled by licensed or experimental vaccines. In this review, we examine challenges that have impeded development of effective mucosal respiratory vaccines, emphasizing that all of these viruses replicate extremely rapidly in the surface epithelium and are quickly transmitted to other hosts, within a narrow window of time before adaptive immune responses are fully marshaled. We discuss possible approaches to developing next-generation vaccines against these viruses, in consideration of several variables such as vaccine antigen configuration, dose and adjuventation, route and timing of vaccination, vaccine boosting, adjunctive therapies, and options for public health vaccination polices.

The vaccines for these two very different viruses have common characteristics: they elicit incomplete and short-lived protection against evolving virus variants that escape population immunity.

They replicate predominantly in local mucosal tissue, without causing viremia, and do not significantly encounter the systemic immune system or the full force of adaptive immune responses, which take at least five to seven days to mature, usually well after the peak of viral replication and onward transmission to others.

The importance of mucosal secretory IgA (sIgA) in pathogen-specific responses against respiratory viral infections has long been appreciated for influenza viruses, RSV and more recently SARS-CoV-2.

During the COVID-19 pandemic, the rapid development and deployment of SARS-CoV-2 vaccines has saved innumerable lives and helped to achieve early partial pandemic control.

However, as variant SARS-CoV-2 strains have emerged, deficiencies in these vaccines reminiscent of influenza vaccines have become apparent. The vaccines for these two very different viruses have common characteristics: they elicit incomplete and short-lived protection against evolving virus variants that escape population immunity.

Considering that vaccine development and licensure is a long and complex process requiring years of preclinical and clinical safety and efficacy data, the limitations of influenza and SARS-CoV-2 vaccines remind us that candidate vaccines for most other respiratory viruses have to date been insufficiently protective for consideration of licensure, including candidate vaccines against RSV, a major killer of infants and the elderly,parainfluenzaviruses, endemic coronaviruses, and many other “common cold” viruses that cause significant morbidity and economic loss.

https://www.cell.com/cell-host-microbe/fulltext/S1931-3128(22)00572-8

Dr. Fauci Comes Clean About Never Expecting the Vaccines to Work and Natural Immunity Being Better

by Dr David Bell

23 February 2023 9:00 AM

https://dailysceptic.org/2023/02/23/dr-fauci-comes-clean-about-never-expecting-the-vaccines-to-work-and-natural-immunity-being-better/

要するに優秀なファウチせんせは最初から

風邪のようなウイルスに対して有効なワクチンなんてまだまだ無理筋

そして・・・

感染回復による自然免疫＞＞＞＞＞＞＞＞ワクチン由来の短期的かつ不完全な免疫

だと分かってたわけで・・・

さて勇者のSAN値急降下開始のお知らせですかねえ・・・（爆ｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗ